ClinicalTrials.gg
RecruitingNCT07588503Updated May 14, 2026

FES Cycling With BFR in the Spinal Cord Injury Population

A Phase 1 interventional study of Blood Flow Restriction and Functional Electrical Stimulated Cycling in Spinal Cord Injury, Cardio Vascular Disease and Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease, sponsored by Dr. B. Catharine. Craven. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Dr. B. Catharine. Craven · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 204 studies in Spinal Cord Injuries with a site in Canada — 67 open to participants now, 74 under way, 4 of them phase 3. Spinal Cord Injuries · Canada.

Planned enrollment
159th of 179
6 · median 24
Started
2026
with 13 others
Phase 1
8 of 204
4 open now
Primary completion
2027-01
later than 43 of 73 live
Registered
193rd of 204
by date

Among the 204 studies in Spinal Cord Injuries with a site in Canada, this one is the 159th largest by planned enrollment of the 179 interventional ones that give a count, is one of 14 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 43 of the 73 other live ones, and was the 193rd registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

67 of the 204 studies in Spinal Cord Injuries with a site in Canada are open now. Recruiting first, the newest first:

61 more — sign in →

All 67 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies in Spinal Cord Injuries with a site in Canada, or all of them as a file.
02

Study summary

Cardiometabolic Disease (CMD) is the silent killer within the spinal cord injury/disease (SCI/D) population. Many SCI/D patients' initial CMD presentation is with a heart attack, stroke, or sudden cardiac death, highlighting the need for interventions to reduce CMD risk. CMD contributes to 46% of deaths, with 30-50% of the SCI/D population living with undiagnosed CMD. Treating CMD risk is more challenging in the SCI/D population due to prolonged inactivity, inability to exercise, and excessive caloric intake to expenditure ratio. Identifying accessible and inclusive strategies to combat CMD risk in the SCI/D population is a compelling and urgent health priority.

Blood flow restriction (BFR) exercise involves applying inflatable cuffs to the proximal end of an individual's limbs. Changes to the amount of blood flowing into and out of the limb lead to a low oxygen environment within the limb, shifting the way the muscles can produce the energy required to function, increasing the benefits of low- and moderate-intensity exercise. Coupling BFR with Functional electrical stimulation cycling (FES-cycling), a commonly used rehabilitation tool within the SCI population, could improve FES-cycling's short- and long-term benefits without reducing the accessibility and inclusiveness of long-term exercise prescription. Although preliminary BFR research in the SCI/D has identified positive muscular improvements, whether FES-cycling coupled with BFR can be safely prescribed or feasibly implemented long-term within the SCI/D population is unknown.

The proposed project aims to determine the safety and feasibility of FES-cycling coupled with BFR for 20 minutes of moderate-intensity exercise among adults with chronic spinal cord injury/disease (SCI/D). The research team aims to implement pre-test, eight exercise sessions, and post-test across 6-weeks. Criteria for success include no adverse or severe adverse events not alleviated by ceasing exercise (safety), a 1 to 8 ratio of participants screened to participants eligible (recruitment success), and participants successfully completing all exercise sessions (participant retention).

Read the detailed description

Background Spinal cord injury/disease (SCI/D) is a highly debilitating condition that results in motor, sensory, autonomic, and autoimmune impairments, which dramatically alters the individual's mobility, life, and health. Following injury, the individual's health is compromised by their primary impairment and secondary health conditions. Cardiometabolic Disease (CMD) refers to a collection of interrelated conditions (e.g., insulin resistance, chronic inflammation, and obesity) that increase the risk of cardiovascular and metabolic disease. CMD disease contributes to 46% of deaths within the SCI/D population. Currently, limited rehabilitation strategies exist that can effectively combat CMD risk factors among individuals living with an SCI/D. Therefore, identifying accessible, inclusive, and safe rehabilitation strategies to combat CMD risk among individuals living with an SCI/D is a compelling and urgent health priority.

Study Aim and Rationale The proposed project aims to investigate the safety and feasibility of functional electrical stimulation cycling (FES-Cycling) coupled with blood flow restriction (BFR). Preliminary studies examining BFR exercise within SCI/D individuals have reported positive findings. However, the pioneering BFR exercise research has not prescribed moderate-intensity aerobic exercise that mirrors the SCI/D weekly exercise guidelines. Therefore, whether BFR can be tolerated safely and practically in the SCI/D population is unknown.

Methods The proposed pilot study will utilize a convergent mixed methods approach and implement a pretest-post test quasi-experimental design. Six adults (18-75yrs) with chronic (>1yr) SCI/D will be recruited to participate in two testing sessions (pre/post), four FES-Cycling exercise sessions, and four FES-cycling coupled with BFR sessions across six weeks. Measures of safety, participant recruitment, and retention will be collected. A criterion of success will be developed for each measure. Descriptive statistics will be calculated and compared to the prior-defined success criterion. Deductive and inductive content analysis will assess participant feedback regarding exercise modality and protocol implementation.

Anticipated Results The research team expects to accomplish the success criteria for all measurement categories based on the existing evidence across the domains of FES-cycling and BFR exercise within SCI/D. Analysis of participant feedback will direct future protocol development and BFR prescription parameters.

Conclusions The proposed project is the first step towards developing a low-cost, highly accessible exercise accessory that could potentially maximize the physiological yield of aerobic and resistance exercise, increasing the potential protective abilities of exercise against CMD risk.

03

Conditions studied

  • Spinal Cord Injury
  • Cardio Vascular Disease
  • Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease

Keywords

  • Safety
  • Feasability
  • Spinal Cord Injury
  • Blood Flow Restricted Aerobic Exercise
  • Functional Electrical Stimulation
  • Cycling
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (≥ 18 to ≤ 75yrs)
  • Male or female
  • Chronic Injury (>1yr)
  • Diagnosis of SCI at levels between C5 to T10 (AIS A-D) with traumatic or non-traumatic etiology.
  • ≥3 Cardiometabolic risk parameters

Exclusion criteria

Exclusion Criteria:

  • A prior or current history of venous thromboembolism
  • Pressure injury of the pelvis, mid to upper thigh region, or foot
  • Managing a lower limb fracture
  • Any history of embolic stroke
  • Myocardial infarction
  • Current untreated hypertension
  • Language, psychiatric, cognitive, or communicative disability (e.g., traumatic brain injury) that compromises the participant's autonomy to voluntarily join the study, follow its instructions and/or operate the device.
  • Current alcohol or street drug use disorder.
  • Current use of an anticoagulant medication.
  • Frequent episodes of autonomic dysreflexia unresponsive to therapy (e.g., 3-5 times a week).
  • Unresolved deep vein thromboembolism (VTE) in the past six months.
  • Severe spasticity preventing the necessary range of motion for cycling.
  • Active implantable medical device (e.g., pacemaker, ITB pump).
  • Inability to provide .
  • Severe active concurrent medical conditions (e.g., skin or respiratory infections, lung, pressure sores).
  • Unstable spine or unhealed limbs or pelvic fractures.
  • Active heterotopic ossification interfering with the lower extremity range of motion.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Active comparator
    Functional Electrical Stimulated Cycling

    Four FES-Cycling exercise sessions. Participants will complete 20 minutes of exercise two times a week for 2 weeks.

    Other: Functional Electrical Stimulated Cycling

  • Active comparator
    Functional Electrical Stimulated Cycling with Blood Flow Restriction

    Four FES-Cycling with BFR exercise sessions. Participants will complete 20 minutes of exercise two times a week for 2 weeks.

    Device: Blood Flow Restriction · Other: Functional Electrical Stimulated Cycling

Interventions

  • DeviceBlood Flow Restriction

    Blood Flow Restriction (BFR) exercise is a training method where a specialized cuff or band is applied to the top of a limb (arm or leg) to partially restrict blood flow during exercise.

    Also known as: KAATSU

  • OtherFunctional Electrical Stimulated Cycling

    Electrical impulses will be sent to the muscles of the lower leg during cycling to facilitate muscular contractions.

06

What researchers measure

Primary outcomes

  1. Participant Retention

    For a long-term clinical trial spanning 3 to 6 months of data collection per participant, the research team would estimate an approximate retention rate of 80%. Therefore, our criteria for successful participant retention as a feasibility assessment is having a maximum of two recruited participants who do not complete the 4-week protocol.

    Time frame: Six weeks - From enrollment to the end of the exercise protocol.

  2. Safety - Skin Checks

    Pre/post-session skin checks will be performed and findings recorded as a metric of safety.

    Time frame: 6 weeks

  3. Safety - Adverse Event Report

    Any adverse or serious adverse events will be reported as per the hospital policy.

    Time frame: 6 weeks

  4. Recruitment Rate

    Our criteria for success in recruiting six participants is 2 to 3 months. The time taken to successfully recruit 6 participants will be reported.

    Time frame: 2 to 3 months, depending on how successful the recruitment process is.

  5. Change in CMD Risk Profile - Lipid Profile

    Participants will have a blood draw pre- and post-exercise intervention. Participants' fasting lipid profiles will be assessed. All aspects will be reported as millimoles per litre (mmol/L) and will involve: total cholesterol, low-density cholesterol, high-density cholesterol and triglycerides.

    Time frame: Six weeks - From enrollment to the end of the exercise protocol.

  6. Participant Perspectives and Experience

    Participant satisfaction is fundamental to implementing a successful long-term clinical trial. The interview guide will use a combination of structured and semi-structured interview techniques during the follow-up session to gain the participant's perspectives on the implemented protocol, elements they enjoy and elements they did not. After study completion, one-on-one semi-structured interviews (in-person or via MS Teams) lasting approximately 45-60 minutes will be conducted to explore participants' perceptions of recruitment approaches, elements they enjoy and elements they did not. Interviews will be voiced record and word for word transcribed for batch analysis at the completion of the entire study. This will allow us to look beyond the efficacy of the novel exercise technique and consider its level of practicality, acceptability and scalability within the SCI population. Participants that choose to withdraw will not be interviewed.

    Time frame: 6 weeks

  7. Safety - Heart Rate

    Heart rate will be measured at fixed time points pre- and post-session and continuously throughout the exercise period. Heart Rate will be recorded as beats per minute.

    Time frame: Six weeks - From enrollment to the end of the exercise protocol.

  8. Safety - Blood Pressure

    Blood pressure will be recorded at a fixed time point pre- and post-session, and at two-minute increments throughout the exercise period. Systolic and Diastolic blood pressure will be reported as millimetres of mercury.

    Time frame: Six weeks - From enrollment to the end of the exercise protocol.

  9. Safety - Oxygen Saturation

    Oxygen saturation will be collected at a fixed time point pre- and post-session, and at two-minute increments throughout the exercise period. Oxygen saturation will be measured as a percentage of available hemoglobin binding sites occupied by oxygen.

    Time frame: Six weeks - From enrollment to the end of the exercise protocol.

  10. Safety - Rating of Perceived Exertion and Discomfort.

    Ratings of perceived exertion and discomfort will be recorded at two-minute increments during the exercise period and at a fixed time point post-exercise. Both perceived exertion and discomfort will be rated on a scale from 0 to 10.

    Time frame: Six weeks - From enrollment to the end of the exercise protocol.

  11. Change in CMD Risk Profile - C-Reactive Protein

    Participants will have a blood draw pre- and post-exercise intervention. Participants' C-Reactive Protein levels will be reported as milligrams per litre (mg/L).

    Time frame: Six weeks - From enrollment to the end of the exercise protocol.

  12. Change in CMD Risk Profile - Hemoglobin A1c

    From the Pre-/post-intervention blood draws participant's Hemoglobin A1c will be reported as a percentage (%).

    Time frame: Six weeks - From enrollment to the end of the exercise protocol.

  13. Change in CMD Risk Profile - Fasted Plasma Glucose

    From the pre-/post-intervention blood draws, participants' Fasted Plasma Glucose will be reported as millimoles per litre (mmol/L).

    Time frame: Six weeks - From enrollment to the end of the exercise protocol.

  14. Change in CMD Risk Profile - Waist Circumference

    Pre- and Post-intervention participants' waist circumference will be measured and reported (cm)

    Time frame: Six weeks - From enrollment to the end of the exercise protocol.

  15. Change in CMD Risk Profile - Body Mass Index

    Pre- and Post-intervention participants height (cm) and weight (kg) will be recorded and Body Mass index calculated and reported (kg/m²)

    Time frame: Six weeks - From enrollment to the end of the exercise protocol.

07

Study locations

1 of 1 sites recruiting
  • Lyndhurst Centre
    Toronto, Ontario M4G 3V9, Canada
    Recruiting
    • Thomas P Walden, Ph.D · Contactthomas.walden@uhn.ca · 4165973422
    • Katherine Chan, MSc · ContactKatherine.chan@uhn.ca · 4165973422
    • B.Catharine Craven, MD · Principal investigator
    • Kristin Musselman, Ph.D · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Summary data of the primary variables

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jan 2027, 6 months later.

Of 40 non-industry phase 1 interventional studies under Spinal Cord Injuries, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 55. This study's planned 6 months is below that.

Counting every sponsor, half of 51 studies reached it within 36 months; a quarter within 24 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
May 14, 2026
StartEst.
Jun 15, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Sep 30, 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07588503
Lead sponsor
Dr. B. Catharine. Craven
Collaborators
CAN-TAP-TALENT (CIHR Stream)
Responsible party
Dr. B. Catharine. Craven (Senior Scientist - Principal Investigator, Toronto Rehabilitation Institute) — Sponsor-investigator
First posted
May 14, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
May 14, 2026

Study contacts

Thomas P Walden, Ph.D
Contact
thomas.walden@uhn.ca
4165973422 ext. 6287
Katherine Chan, MSc
Contact
Katherine.chan@uhn.ca
4165973422 ext. 6199

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion